...London, U.K.) for its anti-inflammatory program; point-of-care diagnostic company OJ-Bio Ltd. (Newcastle, U.K.); cancer company Pharminox Ltd....

...U.K. Not available Particle Therapeutics Ltd. Drug delivery and reformulation 2006 Oxford, U.K. Not available Pharminox Ltd....

...additional cell lines and animal models are necessary to further validate the compounds' therapeutic potential. Pharminox Ltd.'s...

...Pharminox and SGP partnered to discover small molecule cancer therapeutics. Pharminox will synthesize compounds, which SGP...
...anti-tumor activity. SGP will have the exclusive option to license worldwide rights to resulting IP. Pharminox...
...than $40 million, including research funding for up to two years and milestones, plus royalties. Pharminox Ltd....

...Cancer Research's Cancer Research Technology Ltd. subsidiary granted Pharminox an exclusive 12-month option to in-license exclusive...
...telomere signaling targeted agents. The lead compound, RHPS4 , is in preclinical development for cancer. Pharminox Ltd....

...203). A U.K. Phase I trial of the compound is ongoing. Under a 2003 deal, Pharminox...
...and commercialization rights from Cancer Research to a series of preclinical quinols to treat cancer. Pharminox Ltd....